File

Structural heart disease

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure,...

Dr. Carlos Fava - 24 June, 2025

Learn More

Chronic Coronary Syndromes

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which...

Dr. Omar Tupayachi - 20 June, 2025

Learn More

Mitral valve

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative...

Dr. Juan Manuel Pérez - 20 June, 2025

Learn More

Mitral valve

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently...

Dr. Carlos Fava - 20 June, 2025

Learn More

Left Atrial Apendix Closure

Watchman FLX and Improvement Impact vs. 2.5

Left atrial appendage occlusion (LAAO) represents an effective alternative to oral anticoagulation (OAC) in patients with non-valvular...

Dr. Omar Tupayachi - 17 June, 2025

Learn More

Chronic Coronary Syndromes

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an...

Dr. Omar Tupayachi - 17 June, 2025

Learn More

Acute coronary syndromes

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to...

Dr. Andrés Rodríguez - 11 June, 2025

Learn More

Acute coronary syndromes

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as...

Dr. Andrés Rodríguez - 11 June, 2025

Learn More

Heterotopic Treatment of the Tricuspid Valve

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Edge-to-Edge Treatment in Cardiogenic Shock

Watchman FLX and Improvement Impact vs. 2.5

Chronic Stent Recoil and Its Long-Term Effects

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Access